A phase I/II study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of FR104, a novel antagonist pegylated anti-CD28 Fab’ antibody fragment in de novo renal transplant patients
Phase 1/2
Completed
- Conditions
- Kidney transplant
- Registration Number
- 2024-516577-76-00
- Lead Sponsor
- Centre Hospitalier Universitaire De Nantes
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ended
- Sex
- Not specified
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Centre Hospitalier Universitaire De Nantes
🇫🇷Nantes, France
Centre Hospitalier Universitaire De Nantes🇫🇷Nantes, FranceGilles BlanchoSite contact0240087782gilles.blancho@chu-nantes.fr